Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01876368 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
A Phase 3 study of Hypertension, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
- 20
- Study locations
NCT01876368 is a Phase 3 study of Hypertension that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 376 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT01876368, a Phase 3 study of Hypertension, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan
Conditions Studied
Interventions
- DRUG LCZ696
- DRUG Olmesartan
- DRUG Placebo of LCZ696
- DRUG Placebo of Olmesartan
Study Locations (20)
California
- Novartis Investigative Site - Fair Oaks
- Novartis Investigative Site - Hawaiian Gardens
- Novartis Investigative Site - Long Beach
- Novartis Investigative Site - Los Angeles
- Novartis Investigative Site - Orangevale
- Novartis Investigative Site - Westlake Village
Georgia
- Novartis Investigative Site - Atlanta
- Novartis Investigative Site - Conyers
Illinois
- Novartis Investigative Site - Chicago
- Novartis Investigative Site - Chicago
Mississippi
- Novartis Investigative Site - Belzoni
- Novartis Investigative Site - Jackson
Oregon
- Novartis Investigative Site - Oregon City
- Novartis Investigative Site - Portland
Alabama
- Novartis Investigative Site - Birmingham
Colorado
- Novartis Investigative Site - Denver
Kansas
- Novartis Investigative Site - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01876368
The ClinicalTrials.gov registry entry for NCT01876368 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (89% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 4 interventions - of which LCZ696 is the first listed.
NCT01876368 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT01876368 about?
NCT01876368 is a clinical study titled "Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan". This study will assess the efficacy and safety of LCZ696 in comparison to olmesartan in essential hypertensive patients not adequately responsive to olmesartan
What is the current status of trial NCT01876368?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2013-09. Estimated completion is 2014-08.
What conditions does trial NCT01876368 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT01876368?
The interventions under investigation include: LCZ696 (DRUG), Olmesartan (DRUG), Placebo of LCZ696 (DRUG), Placebo of Olmesartan (DRUG).
Who is sponsoring clinical trial NCT01876368?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01876368 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.